- This event has passed.
Seminar One – Leaders at the Forefront: Charting the Course for Victorian Medtech Manufacturing
March 28, 2023 @ 7:20 am - 9:30 am AEDT
Event Navigation
Medtech Manufacturing Series
In partnership with the Australian Medtech Manufacturing Centre (AMMC), BioMelbourne Network is excited to deliver a four-part seminar series for the Victorian medtech manufacturing sector.Victorian medtech manufacturers produce cutting-edge, high-quality products and have the capability and ambition to scale, backed by a strong R&D ecosystem. Through a series of keynote presentations, panel discussions and networking functions, the series will showcase local success stories, highlight the capabilities of Victoria-based manufacturers and explore the impact on the local economy.By providing access to industry experts, networks, and resources, the series aims to strengthen the growth and development of the local medtech sector, helping to bring new innovations to market and drive the future economic growth of Victoria.
Seminar One – Leaders at the Forefront: Charting the Course for Victorian Medtech Manufacturing
As a professional in the medical technology sector, you are aware of the importance of staying ahead of the curve and exploring new opportunities for growth and development.Join us on Tuesday 28 March for an engaging networking event exploring the Victorian manufacturing landscape and sovereign capability in the sector.Our leading industry experts will showcase Australian manufacturing capabilities and talent, and delve into the future of Victorian manufacturing and its impact on the local economy. The event will provide an opportunity to connect with like-minded professionals and engage in lively discussions on the current state and future direction of medtech manufacturing within the industry.We look forward to your attendance at this thought-provoking event.
Who should attend?
- Medtech manufacturers, supply chain partners, SMEs, startups and industry service providers
- Medical technology executives developing and/or manufacturing products for market
- Health services professionals seeking to improve knowledge and expertise in medical devices and diagnostics
- CEOs, CSOs, CTOs, procurement leads, product developers, product designers, engineers, scientists and researchers.
Seminar One details:
Date: Tuesday 28 March 2023
Time (AEDT):
7:20am: Guest arrival and registration
7:20am – 8:00am: Stand-up networking breakfast
8:00am – 9:30am: Presentations and panel
Format: Hybrid – In-person and online
Venue: Cliftons Freshwater, Level 18/2 Southbank Blvd, Southbank VIC 3006
Guest speakers from: CSIRO, Invetech, SDI Limited, and Zip Diagnostics.
Host: Jeff Malone, CEO, BioMelbourne Network
Registration:
In-person: Members $85; Non Members $175
Online: Members $25; Non Members $45
This seminar series is delivered in partnership with AMMC– an initiative of the Victorian Government
Cancellation Policy
In-person registration:
Full refund given up to 7 days prior to the event
No refunds within 7 days of the event
Online registration:
Full refund given up to 3 days prior to the event
No refunds within 3 days of the event
Professor Susie Nilsson, Research Director, Biomedical Manufacturing, CSIRO
Prof Susie Nilsson is the Research Director for the Biomedical Manufacturing program with CSIRO (the Commonwealth Science and Industry Research Organisation), Australia’s National Science Agency.
Her portfolio encompasses the production of new products and processes for the biomedical sector – medical devices, diagnostics, drugs, vaccines, and efficient processes to produce them. This covers regulated biomanufacturing, biologics research and development, chemical biology, diagnostics and devices and bioactive small molecules and polymers.
Susie has an extensive history in biologics and specifically haematopoietic stem cell research. She completed her PhD at Melbourne University and post-doctoral studies at the University of Massachusetts prior to taking up a position at the Peter MacCallum Cancer Institute then the Australian Stem Cell Centre. She moved to CSIRO in 2009 and was appointed as an Australian Research Council Future Fellow. She became a group leader at the Australian Regenerative Medical Institute, Monash University in 2013 and a CSIRO Science Leader in 2014.
Her current role sees broad contributions including overseeing the production of biologics for Phase I clinical trials, recently exemplified by the production of two COVID-19 vaccine candidates, the building of the new National Vaccine and Therapeutics Laboratory for producing products in mammalian and insect systems for Phase I and II/III clinical trials as well as the growth of interactions with industry in key areas or of the biomedical sector.
Her portfolio encompasses the production of new products and processes for the biomedical sector – medical devices, diagnostics, drugs, vaccines, and efficient processes to produce them. This covers regulated biomanufacturing, biologics research and development, chemical biology, diagnostics and devices and bioactive small molecules and polymers.
Susie has an extensive history in biologics and specifically haematopoietic stem cell research. She completed her PhD at Melbourne University and post-doctoral studies at the University of Massachusetts prior to taking up a position at the Peter MacCallum Cancer Institute then the Australian Stem Cell Centre. She moved to CSIRO in 2009 and was appointed as an Australian Research Council Future Fellow. She became a group leader at the Australian Regenerative Medical Institute, Monash University in 2013 and a CSIRO Science Leader in 2014.
Her current role sees broad contributions including overseeing the production of biologics for Phase I clinical trials, recently exemplified by the production of two COVID-19 vaccine candidates, the building of the new National Vaccine and Therapeutics Laboratory for producing products in mammalian and insect systems for Phase I and II/III clinical trials as well as the growth of interactions with industry in key areas or of the biomedical sector.
Dr Damian Verdnik, Head of Diagnostics, Invetech
Dr Damian Verdnik is Head of Diagnostics at Invetech in Melbourne.
He has been working in scientific and medical device product development for 25 years, starting his career at Axon Instruments in the 1990s when he worked for Axon founder Dr Alan Finkel. At Axon Damian was product manager for DNA microarray and cell imaging software that used novel image analysis and machine learning techniques, an experience which has led to his ongoing interest in AI and its application to medical diagnostics.
Damian has been at Invetech since 2007. In his current role as Head of Diagnostics Damian leads a large team of consulting engineers, scientists and program managers in Australia and the US who specialise in the design and manufacture of diagnostic instruments, software and medical devices. Invetech has ISO13485 and FDA-registered contract manufacturing facilities in Melbourne and Boxborough MA, USA, and manufactures for clients worldwide.
Damian has double honours degrees in mathematical physics and philosophy from ANU, and a PhD in philosophy from Monash University.
He has been working in scientific and medical device product development for 25 years, starting his career at Axon Instruments in the 1990s when he worked for Axon founder Dr Alan Finkel. At Axon Damian was product manager for DNA microarray and cell imaging software that used novel image analysis and machine learning techniques, an experience which has led to his ongoing interest in AI and its application to medical diagnostics.
Damian has been at Invetech since 2007. In his current role as Head of Diagnostics Damian leads a large team of consulting engineers, scientists and program managers in Australia and the US who specialise in the design and manufacture of diagnostic instruments, software and medical devices. Invetech has ISO13485 and FDA-registered contract manufacturing facilities in Melbourne and Boxborough MA, USA, and manufactures for clients worldwide.
Damian has double honours degrees in mathematical physics and philosophy from ANU, and a PhD in philosophy from Monash University.
Samantha Cheetham, CEO & Managing Director, SDI
Samantha Cheetham is the CEO of SDI Limited, Australia’s largest dental manufacturer. SDI conducts research and development, manufacturing and sales of dental filling materials, cements, adhesives and tooth whitening. SDI is an advanced medical device manufacturer and recently won the 2022 Governor of Victoria’s Victorian Exporter of the Year Award, plus the International Health Award.
Samantha has worked at SDI for over 30 years. Starting as a sales representative in Melbourne, she then transferred to the USA, working as a regional sales manager in San Francisco. After several years in the role, she became VP of sales until she transferred back to Melbourne to become the global sales and marketing manager, then finally to CEO in 2016. Samantha has a Bachelor of Business (Monash) and an MBA (Melbourne).
Samantha plays a key role in SDI’s product development and future product pipeline. Focusing on unique materials and innovative delivery systems, SDI is a world leader in pioneering products for dentists to provide better health for their patients.
Samantha has worked at SDI for over 30 years. Starting as a sales representative in Melbourne, she then transferred to the USA, working as a regional sales manager in San Francisco. After several years in the role, she became VP of sales until she transferred back to Melbourne to become the global sales and marketing manager, then finally to CEO in 2016. Samantha has a Bachelor of Business (Monash) and an MBA (Melbourne).
Samantha plays a key role in SDI’s product development and future product pipeline. Focusing on unique materials and innovative delivery systems, SDI is a world leader in pioneering products for dentists to provide better health for their patients.
Associate Professor Jack Richards, Co-Founder and Scientific Director, Zip Diagnostics
Associate Professor Jack Richards founded ZiP Diagnostics 3 years ago. He has been a practicing infectious diseases physician for 18 years and has a passion for improving patient care and public health. He has a particular interest in low-middle income countries and has worked extensively the Asia-Pacific and African regions.
He founded ZiP Diagnostics to develop and manufacture the next generation of point-of-care tests. These tests enable healthcare professionals to have immediate test results to initiate targeted clinical management. This results in improved patient engagement, enables informed clinical decision-making and overcomes the current delays in patient care arising from centralised lab-based testing.
ZiP Diagnostics has a mission to provide rapid, accurate, low-cost point-of-care tests for infectious diseases to meet global diagnostic needs.
He founded ZiP Diagnostics to develop and manufacture the next generation of point-of-care tests. These tests enable healthcare professionals to have immediate test results to initiate targeted clinical management. This results in improved patient engagement, enables informed clinical decision-making and overcomes the current delays in patient care arising from centralised lab-based testing.
ZiP Diagnostics has a mission to provide rapid, accurate, low-cost point-of-care tests for infectious diseases to meet global diagnostic needs.
Related Events
